Diffuse Large B-cell Lymphoma Prognosis (NCCN-IPI)
Estimate prognosis in diffuse large B-cell lymphoma
The original International Prognostic Index (IPI) was developed and validated prior to the addition of rituximab to curative anthracycline-based chemotherapy.
Clinical trials have confirmed that rituximab improves the survival of individuals with diffuse large B-cell lymphoma. Using a database of patients treated in the rituximab era (the National Comprehensive Cancer Network database consisting of 1935 patients), this enhanced IPI score is able to discriminate individuals based on 5 clinical predictors (and an 8 point scoring system).
The final score is able to differentiate patients into four distinct prognostic groups for overall survival (low, low-intermediate, high-intermediate, and high risk).
The original IPI was developed by Shipp et al.
The enhanced NCCN-IPI offers improved discrimination for the overall survival of low- and high-risk patients in the rituximab era.
Shipp et al.
Zhou et al.